
Aster DM Quality Care Q1: PAT crashes on ₹114cr merger cost; EBITDA still +27.5% YoY
hospital chain · healthcare · merger integration

hospital chain · healthcare · merger integration

biosimilars growth · margin expansion · crdmo headwinds

api cdmo · sterile apis · margin normalization

deferred tax reversal · margin expansion · biologics cdmo

pharmaceuticals · consolidated results · margin expansion

diagnostics · pathology services · margin expansion

promoter exit · private equity acquisition · ChrysCapital

pharma · cdmo · margin expansion

us generics ramp · margin compression · revenue beat

eye care · hospital chain · margin expansion

Acquisition · Private Equity · Pharma



specialty generics · ANDA approvals · oncology pivot

margin sustainability · merger integration · facility expansion

generic pharma · USFDA approval · Sugammadex launch

hospital margins · diagnostics growth · capacity expansion

hospitals · healthcare · margin compression

eye care · hospital chain · net margin expansion

hospitals · healthcare services · margin expansion

hospitals · healthcare services · margin expansion

skin care · hair care · standalone loss

hospitals · healthcare services · bed capacity expansion

healthcare · merger · integration

CDMO · capex · EBITDA margins

biosimilars · margin expansion · Gennova

revenue growth · US FDA approvals · margin trajectory

diabetes growth · insulin portfolio · margins

oncology · specialty medicines · vaccines

margin recovery · BBL consolidation · biosimilar momentum